StephenAnthonyStricklandJr.MDMD, MSCI

Hematology • Nashville, TN

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Director of Leukemia Research at Sarah Cannon Research Institute

Join to view full profile

Dr. Strickland is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Strickland's full profile

Already have an account?

Office
2410 Patterson Street
Suite 500
Nashville, TN 37203
Phone+1 615-342-7440

Education & Training

Vanderbilt University School of MedicineMaster of Science in Clinical Investigation, 2007 - 2010
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Vanderbilt University Medical CenterResidency, Internal Medicine, 2002 - 2005
Louisiana State University School of Medicine in New OrleansClass of 2002, MD
Barry UniversityMS, Biomedical Sciences, 1995 - 1996
Louisiana State UniversityBachelors, Zoology and Physiology, 1991 - 1995

Certifications & Licensure

TN State Medical License 2005 - 2025
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML) Start of enrollment: 2008 Oct 01
Completed
Phase 1
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Start of enrollment: 2010 Jun 10
Completed
Phase 1, Phase 2
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) Start of enrollment: 2010 Oct 01
Completed
Phase 1
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Start of enrollment: 2011 May 01
Completed
Phase 2
Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission Start of enrollment: 2012 Jul 01
Terminated
Phase 1, Phase 2
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2016 Apr 20
Active, not recruiting
Phase 2
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
No longer available
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia Start of enrollment: 2016 Mar 01
Active, not recruiting
Phase 2
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia Start of enrollment: 2016 Jul 21
Completed
Phase 2
SEL24/MEN1703 in Patients With Acute Myeloid Leukemia Start of enrollment: 2017 Mar 10
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

450 citations
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Andrew H. Wei, Stephen A. Strickland, Jing Zhou Hou, Walter Fiedler, Tara L. Lin
Journal of Clinical Oncology. 2019-03-20
356 citations
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
Alexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Mark R. Litzow
The Lancet. Oncology. 2017-08-01
589 citations
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute My...
Jeffrey E. Lancet, Geoffrey L. Uy, Jorge E. Cortes, Laura F. Newell, Tara L. Lin
Journal of Clinical Oncology. 2018-07-19

Abstracts/Posters

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
Stephen A. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...
Stephen A. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
Stephen A. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia
Stephen A. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Int...
Stephen A. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...
Stephen A. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
Stephen A. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018